Amgen Beats Decade-Old Investor Suit Over Off-Label Scheme

Law360, Los Angeles (January 10, 2017, 10:25 PM EST) -- A California judge Tuesday dismissed a decade-old action claiming Amgen Inc.’s board caused more than $1 billion in damages by overseeing an off-label drug marketing scheme, saying the shareholder failed to make a demand on the officials to instigate litigation before filing her suit.

Shareholder Judy Durgin’s suit, brought in May 2007, relates to allegedly misleading statements the pharmaceutical giant made about off-label uses for two of its drugs, Aranesp and Epogen. In 2012, the company pled guilty in federal court to misbranding Aranesp and agreed...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Judy Durgin v. Kevin W Sharer et al


Case Number

2:07-cv-03001

Court

California Central

Nature of Suit

Stockholders Suits

Judge

Philip S. Gutierrez

Date Filed

May 7, 2007

Law Firms

Companies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.